Primary liver cancer genome sequencing: translational implications and challenges

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Kyrochristos ID, Glantzounis GK, Ziogas DE, et al. From clinical standards to translating next-generation sequencing research into patient care improvement for hepatobiliary and pancreatic cancers. Int J Mol Sci. 2017;18(1):180.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al., Group SIS. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al., Investigators R. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.
   PubMed Web of Science ®Google Scholar
• Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135–1145.
   PubMed Web of Science ®Google Scholar
• Ku CS, Roukos DH. From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine. Expert Rev Med Devices. 2013;10:1–6.
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A, Friedman SL. et al. Liver cancer cell of origin. Molecular class, and effects on patient prognosis. Gastroenterology; 2017 Mar;152(4):745–761.
   PubMed Web of Science ®Google Scholar
• Friedman AA, Letai A, Fisher DE, et al. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15:747–756.
   PubMed Web of Science ®Google Scholar
• Roukos DH. Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies. Drug Discov Today. 2016;21:663–673.
   PubMed Web of Science ®Google Scholar
• Swanton C, Soria JC, Bardelli A, et al. Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Ann Oncol. 2016;27:1443–1448.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495–501.
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Quezada SA, Larkin J, et al. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015;21:1258–1266.
   PubMed Web of Science ®Google Scholar
• Jamieson NB, Chang DK, Biankin AV. Cancer genetics and implications for clinical management. Surg Clin North Am. 2015;95:919–934.
   PubMed Web of Science ®Google Scholar
• Biankin AV, Piantadosi S, Hollingsworth SJ. Patient-centric trials for therapeutic development in precision oncology. Nature. 2015;526:361–370.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
   PubMed Web of Science ®Google Scholar
• Hepatobiliary Cancers, Version 2.2016. NCCN Clinical Practice Guidelines in Oncology. 2016. Available from: www.nccn.org.
   Google Scholar
• Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261:947–955.
   PubMed Web of Science ®Google Scholar
• Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248:84–96.
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al.; investigators S. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354.
   PubMed Web of Science ®Google Scholar
• Cainap C, Qin S, Huang WT, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172–179.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–255.
   PubMed Web of Science ®Google Scholar
• Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013;12:1322–1331.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148:1383–91 e6.
   PubMed Web of Science ®Google Scholar
• U.S Food and Drug Administration [Internet]. Maryland, USA: Department of Health and Human Services; [ cited 2017 Jan 22]. Available from: http://www.fda.gov/
   Google Scholar
• Stamatoyannopoulos JA. What does our genome encode? Genome Res. 2012;22:1602–1611.
   PubMed Web of Science ®Google Scholar
• Gerstein MB, Kundaje A, Hariharan M, et al. Architecture of the human regulatory network derived from ENCODE data. Nature. 2012;489:91–100.
   PubMed Web of Science ®Google Scholar
• Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
   PubMed Web of Science ®Google Scholar
• Mod EC, Roy S, Ernst J, et al. Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science. 2010;330:1787–1797.
   PubMed Web of Science ®Google Scholar
• Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464:999–1005.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas, National Cancer Institute, National Human Genome Research Institute [Internet]; [ cited 2017 Feb 1]. Available from: https://cancergenome.nih.gov/.
   Google Scholar
• International Cancer Genome Consortium [Internet]; [ cited 2017 Feb 1]. Available from: http://icgc.org/.
   Google Scholar
• Roychowdhury S, Chinnaiyan AM. Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin. 2016;66:75–88.
   PubMed Web of Science ®Google Scholar
• Munchel S, Hoang Y, Zhao Y, et al. Targeted or whole genome sequencing of formalin fixed tissue samples: potential applications in cancer genomics. Oncotarget. 2015;6:25943–25961.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20:682–688.
   PubMed Web of Science ®Google Scholar
• Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122:3838–3847.
   PubMed Web of Science ®Google Scholar
• Hofmann D, Nitz U, Gluz O, et al. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 2013;14:261.
   PubMed Web of Science ®Google Scholar
• Chantrill LA, Nagrial AM, Watson C, et al., Australian Pancreatic Cancer Genome I, Individualized Molecular Pancreatic Cancer Therapy Trial Management Committee of the Australasian Gastrointestinal Trials G. Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial. Clin Cancer Res. 2015;21:2029–2037.
   PubMed Web of Science ®Google Scholar
• Hirotsu Y, Zheng TH, Amemiya K, et al. Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma. Hepatol Res. 2016;46:1145–1151.
   PubMed Web of Science ®Google Scholar
• Lu J, Yin J, Dong R, et al. Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next generation sequencing. Mol Med Rep. 2015;12:4678–4682.
   PubMed Web of Science ®Google Scholar
• Janku F, Kaseb AO, Tsimberidou AM, et al. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. 2014;5:3012–3022.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19:235–242.
   PubMed Web of Science ®Google Scholar
• Yoo KH, Kim NK, Kwon WI, et al. Genomic alterations in biliary tract cancer using targeted sequencing. Transl Oncol. 2016;9:173–178.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45:1470–1473.
   PubMed Web of Science ®Google Scholar
• Kaibori M, Sakai K, Ishizaki M, et al. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget. 2016 Aug 2;7(31):49091–49098.
   PubMed Web of Science ®Google Scholar
• Sakai K, Takeda H, Nishijima N, et al. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. Oncotarget. 2015;6:21636–21644.
   PubMed Web of Science ®Google Scholar
• Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9:e115383.
   PubMed Web of Science ®Google Scholar
• Ruzzenente A, Fassan M, Conci S, et al. Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients. Ann Surg Oncol. 2016;23:1699–1707.
   PubMed Web of Science ®Google Scholar
• Kawai-Kitahata F, Asahina Y, Tanaka S, et al. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol. 2016;51:473–486.
   PubMed Web of Science ®Google Scholar
• Ho DW, Chan LK, Chiu YT, et al. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. Gut. 2017 Aug;66(8):1496–1506.
   PubMed Web of Science ®Google Scholar
• Simbolo M, Fassan M, Ruzzenente A, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget. 2014;5:2839–2852.
   PubMed Web of Science ®Google Scholar
• Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016;65:1031–1042.
   PubMed Web of Science ®Google Scholar
• Huang J, Deng Q, Wang Q, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet. 2012;44:1117–1121.
   PubMed Web of Science ®Google Scholar
• Ki Kim S, Ueda Y, Hatano E, et al. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma. Int J Cancer. 2016;139:2512–2518.
   PubMed Web of Science ®Google Scholar
• Kim YH, Hong EK, Kong SY, et al. Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. Oncotarget. 2016;7:23825–23836.
   PubMed Web of Science ®Google Scholar
• Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44:694–698.
   PubMed Web of Science ®Google Scholar
• Cleary SP, Jeck WR, Zhao X, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology. 2013;58:1693–1702.
   PubMed Web of Science ®Google Scholar
• Budzinska MA, Tu T, d’Avigdor WM, et al. Accumulation of deleterious passenger mutations is associated with the progression of hepatocellular carcinoma. PLoS One. 2016;11:e0162586.
   PubMed Web of Science ®Google Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.
   PubMed Web of Science ®Google Scholar
• Ahn SM, Jang SJ, Shim JH, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology. 2014;60:1972–1982.
   PubMed Web of Science ®Google Scholar
• Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505–511.
   PubMed Web of Science ®Google Scholar
• Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014;46:1267–1273.
   PubMed Web of Science ®Google Scholar
• Ouyang L, Lee J, Park CK, et al. Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas. BMC Med Genomics. 2014;7:2.
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Fujimoto A, Furuta M, et al. Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers. PLoS One. 2014;9:e114263.
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012;44:760–764.
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Jiang Z, Stawiski EW, et al. Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol. 2014;15:436.
   PubMed Web of Science ®Google Scholar
• Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44:765–769.
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Furuta M, Shiraishi Y, et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 2015;6:6120.
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Furuta M, Totoki Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016;48:500–509.
   PubMed Web of Science ®Google Scholar
• Zhao LH, Liu X, Yan HX, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun. 2016;7:12992.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–736.
   PubMed Web of Science ®Google Scholar
• Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015;33:1000–1007.
   PubMed Web of Science ®Google Scholar
• Roukos DH. Spatiotemporal diversification of intrapatient genomic clones and early drug development strategy concepts realize the roadmap of precision cancer medicine. Drug Discov Today (Accepted Manuscript). 2017 Apr 8. pii: S1359-6446(17)30163-0. doi: 10.1016/j.drudis.2017.03.014. [Epub ahead of print].
   Web of Science ®Google Scholar
• Klein CA. Selection and adaptation during metastatic cancer progression. Nature. 2013;501:365–372.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46:225–233.
   PubMed Web of Science ®Google Scholar
• Eirew P, Steif A, Khattra J, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2015;518:422–426.
   PubMed Web of Science ®Google Scholar
• Yates LR, Gerstung M, Knappskog S, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21:751–759.
   PubMed Web of Science ®Google Scholar
• Jiang W, Ding Y, Shen Y, et al. Identifying the clonal origin of synchronous multifocal tumors in the hepatobiliary and pancreatic system using multi-omic platforms. Oncotarget. 2017;8:5016–5025.
   PubMed Web of Science ®Google Scholar
• Murugaesu N, Wilson GA, Birkbak NJ, et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 2015;5:821–831.
   PubMed Web of Science ®Google Scholar
• Ziogas DE, Glantzounis G, Liakakos T, et al. Targeting dynamics of subclones of GI, liver and pancreatic cancers. Expert Rev Gastroenterol Hepatol. 2016;10:773–776.
   PubMed Web of Science ®Google Scholar
• Gao Q, Wang ZC, Duan M, et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents. Gastroenterology. 2017;152:232–42 e4.
   PubMed Web of Science ®Google Scholar
• Walter D, Doring C, Feldhahn M, et al. Intratumoral heterogeneity of intrahepatic cholangiocarcinoma. Oncotarget. 2017.
   Web of Science ®Google Scholar
• Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497:108–112.
   PubMed Web of Science ®Google Scholar
• Riediger AL, Dietz S, Schirmer U, et al. Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. Sci Rep. 2016;6:33505.
   PubMed Web of Science ®Google Scholar
• Gremel G, Lee RJ, Girotti MR, et al. Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. Ann Oncol. 2016;27:1959–1965.
   PubMed Web of Science ®Google Scholar
• Liao W, Yang H, Xu H, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget. 2016;7:40481–40490.
   PubMed Web of Science ®Google Scholar
• Chae YK, Davis AA, Carneiro BA, et al. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget. 2016;7:65364–65373.
   PubMed Web of Science ®Google Scholar
• Fox EJ, Loeb LA. Cancer: one cell at a time. Nature. 2014;512:143–144.
   PubMed Web of Science ®Google Scholar
• Chan KC, Jiang P, Zheng YW, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem. 2013;59:211–224.
   PubMed Web of Science ®Google Scholar
• Zill OA, Greene C, Sebisanovic D, et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 2015;5:1040–1048.
   PubMed Web of Science ®Google Scholar
• Zhu W, Zhang XY, Marjani SL, et al. Next-generation molecular diagnosis: single-cell sequencing from bench to bedside. Cell Mol Life Sci. 2017 Mar;74(5):869–880.
   PubMed Web of Science ®Google Scholar